Afferent raises $55m from IPO-focused investors
This article was originally published in Scrip
Executive Summary
San Mateo, California-based Afferent Pharmaceuticals will prepare for a Phase III study for lead drug candidate AF-219 and take a second P2X3 antagonist into the clinic with $55m in venture capital from investors that hope the private company will go public fairly soon.
You may also be interested in...
Merck To Get Chronic Cough P2X3 Inhibitor Candidate With Afferent Buy
A candidate for chronic cough is one of the assets Merck & Co. will get by buying P2X3 inhibitor specialist Afferent Pharmaceuticals Inc, a US-based biotech focusing on chronic pain therapies caused when certain nerves become hypersensitive.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.